IL6 and cancer: Further studies are required to assess (i) the longitudinal phenotype associated with cluster B; (ii) to compare the longitudinal CAR between younger and older adults with cancer, and iii) to assess other well-known biomarker leading to cancer-cachexia, such as proinflammatory cytokines (e.g., Tumour Necrosis Factor-α or Interleukin-6) among older cancer patients.